The UR CTSI now offers two different intuitive, user-friendly, HIPAA-compliant cohort discovery tools to help researchers determine study feasibility, obtain summary patient counts, and identify sites for potential partnerships in multi-site studies: TriNetX and the ACT Network. Both offer a myriad of benefits:
- Real-time, open-access, HIPAA-compliant platforms that provide de-identified summary patient data
- Use for study feasibility, which does not require RSRB approval
- Online self-service with free training and closed captionining available
Query local EMR data and get secure, de-identified summary patient counts to determine the feasibility of your clinical studies.
Validate study feasibility using aggregated EMR data from across the nation and identify potential partner sites for multi-site studies.
Find answers to frequently asked questions about navigating and using TriNetX and ACT, as well as troubleshooting issues.
Which tool is right for you?
- I need to identify the number of UR Medicine patients with a particular set of clinical criteria.
- Use TriNetX
- URMC has enough patients to satisfy my sample size criteria.
- Coming soon: TriNetX will soon have more analytics capabilities.
- URMC does not have enough patients to satisfy my sample size.
- Consider running a multi-site clinical study.
- Use ACT to identify potential collaborating sites with additional patients meeting study criteria.
Questions? Email CTSI_Informatics@urmc.rochester.edu.